GlassScriptPhysician profile
Ali Amirzadeh
NPI 1083748685
$5,381.61
in general payments reported to CMS, 2019-2025
29 companies · $455 in 2025
The $455 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $117 · 2021: $431 · 2022: $1,035 · 2023: $1,912 · 2024: $1,432 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,798.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,798.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,685.13 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $833.54 | 2021-2024 | Nucala, Trelegy Ellipta, Arexvy |
| Genzyme Corporation | $389.33 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $329.65 | 2019-2024 | Dupixent |
| Novartis Pharmaceuticals Corporation | $287.92 | 2021-2025 | |
| Amgen INC. | $244.73 | 2022-2024 | Tezspire |
| Bayer Healthcare Pharmaceuticals INC. | $209.46 | 2023-2025 | |
| Medtronic, INC. | $200.08 | 2024-2025 | Intellis Adaptivestim, Inceptiv |
| Lilly USA, LLC | $157.40 | 2022-2025 | Jardiance, Mounjaro, Zepbound |
| Kaleo, INC. | $145.09 | 2021-2023 | Auvi-Q |
| Takeda Pharmaceuticals U.S.A., INC. | $127.02 | 2022-2023 | Hyqvia, Takhzyro |
| Teva Pharmaceuticals USA, INC. | $87.53 | 2021-2023 | Airduo Digihaler |
| Sanofi-Aventis U.S. LLC | $84.14 | 2025 | |
| Almatica Pharma LLC | $83.16 | 2025 | Teriparatide |
| Genentech USA, INC. | $58.55 | 2023 | Xolair |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Optinose US, INC. | $52.76 | 2021-2023 | |
| Inspire Medical Systems, INC. | $49.74 | 2023 | Inspire |
| Alexion Pharmaceuticals, INC. | $44.00 | 2022-2024 | Strensiq |
| Xeris Pharmaceuticals, INC. | $42.11 | 2025 | Recorlev, Gvoke Hypopen |
| Mannkind Corporation | $37.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $37.31 | 2021-2023 | |
| Novo Nordisk INC | $33.63 | 2023-2025 | Wegovy, Ozempic |
| Tolmar, INC. | $29.42 | 2025 | Jatenzo |
| Aimmune Therapeutics, INC. | $25.67 | 2022 | |
| Grifols USA, LLC | $24.75 | 2024 | Xembify |
| Abbott Laboratories | $22.59 | 2024 | Freestyle Libre 3 |
| Octapharma USA, INC. | $21.06 | 2023 | Cutaquig |
| Radius Health, INC. | $20.36 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Amirzadeh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.